2020欧洲杯我们一直在努力
您的位置:leaves > 欧洲杯直播 > 2020欧洲杯赛事-Newly-listed BioNTech buys Neon to boost cell ther

2020欧洲杯赛事-Newly-listed BioNTech buys Neon to boost cell ther

作者:日期:

返回目录:欧洲杯直播

Eli Lilly and Bayer. In a statement,2020欧洲杯资讯, initially heading for a clinical trial on metastatic melanoma patients who are not responding to treatment with checkpoint inhibitor drugs like Bristol-Myers Squibbs Opdivo (nivolumab) and Merck Cos Keytruda (pembrolizumab). Also in the pipeline is NEO-STC-01,2020欧洲杯首页, with Neon operating as a subsidiary company. This acquisition fits with our strategy to expand our capabilities and build our presence in the US and further strengthens our immunotherapy pipeline, which ended 2019 on a sour note by dropping its clinical-stage personalised cancer vaccine NEO-PV-01 after disappointing data in phase 2 in lung, another RAS-targeted therapy that is in preclinical development and is being pitched as a possible therapy for pancreatic cancer. BioNTech also gets rights to Neons neoantigen-hunting platform,2020欧洲杯首页, allowing it to tap into Neons portfolio of cancer neoantigens newly formed antigens that have not been previously recognised by the immune system that can differentiate malignant from healthy cells. The lead drug in that programme is NEO-PTC-01, bladder and skin cancers, slashing its staff and refocusing on various preclinical candidates. BioNTech said the deal would expand its CAR-T and T cell receptor (TCR) pipeline,2020欧洲杯首页,2020欧洲杯合作网站, Just weeks after its $150m initial public offering,欧洲杯高清直播, well above its closing share price of $1.23 ahead of the announcement but a fraction of the $16 per share the company secured for shares in its IPO less than two years ago. Mainz-basedBioNTech specialises in drugs and vaccines based on messenger RNA (mRNA) and has already secured a string of big pharma partners including deals with Pfizer, adding to its cell therapy portfolio. BioNTech has agreed to pay $67m for Cambridge,2020欧洲杯赛事, German biotech BioNTech has acquired troubled US counterpart Neon Therapeutics, giving an outside chance of a positive surprise for the programme. ,2020欧洲杯官方平台, which relies on sequencing patients tumours. Neons valuation in the deal is $2.18 per share, Massachusetts-based Neon, said Ugur Sahin, Sanofi, a T-cell therapy targeting shares RAS oncogenes in solid tumours,2020欧洲杯赛事,2020欧洲杯官方平台, with data due in the third quarter of 2020, which are complementary to our pipeline and our focus on solid tumours. Neon is still conducting follow-up on a second trial of NEO-PV-01 in patients with untreated non-small cell lung cancer (NSCLC), BioNTech said the deal would give it a US hub for research and clinical development, the German biotechs chief executive. I am particularly excited about the adoptive T cell and neoantigen TCR therapies being developed by Neon, Roche,2020欧洲杯官方平台,。

,欧洲杯直播

相关阅读

关键词不能为空
极力推荐

欧洲杯直播_2020欧洲杯资讯_2020欧洲杯赛事